RxDoctor Payments Data

Lazedra Cade, APRN

Family · Anderson, SCNPI 1043860562

Payments from drug & device makers

$1,310in general payments, 2019–2025

Across 52 payments — averaging $25.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$666
  • Gilead$506
  • Merck$73
  • Lundbeck LLC$31
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$18
  • Johnson & Johnson$17

What the payments were for

  • Food & beverage$1,310100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,310 in reported general payments places this provider in the 70th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$3,031
Medicare patients
17
Services billed
82

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala294$1,126,646
TriumeqAbacavir/Dolutegravir/Lamivudi114$425,130
GenvoyaElviteg/Cob/Emtri/Tenof Alafen62$245,676
TivicayDolutegravir Sodium81$195,524
OdefseyEmtricitab/Rilpiviri/Tenof Ala54$187,290
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf31$140,936
DovatoDolutegravir Sodium/Lamivudine38$107,993
CabenuvaCabotegravir/Rilpivirine14$89,523
JulucaDolutegravir/Rilpivirine25$86,641
DescovyEmtricitabine/Tenofov Alafenam40$83,744
PrezcobixDarunavir/Cobicistat20$46,135
IsentressRaltegravir Potassium12$23,795
Maraviroc15$20,890
VemlidyTenofovir Alafenamide11$14,906
Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf)12$1,257

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy, Vemlidy$506$1,470,971407 claims
Viiv Healthcare CompanyTriumeq, Tivicay, Dovato, Cabenuva, Juluca$666$904,812272 claims
Johnson & JohnsonPrezcobix$17$46,13520 claims
MerckIsentress$73$23,79512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,248 family providers in South Carolina.

Other family in Anderson

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →